Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01606345 · ClinicalTrials.gov registry record · Phase 1
Phase I Study of Percutaneous Valrubicin for Upper Tract Urothelial Carcinoma
A Phase 1 study, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
NCT01606345 is a Phase 1 study that has completed, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 4 participants.
The verdict
NCT01606345, a Phase 1 study, has completed, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
Study Summary
The purpose of this study is to learn more about how well the drug valrubicin (VALSTAR®) works to help treat the patient's cancer when administered through a nephrostomy tube inserted through their back into their kidney. The study is also being done to determine how safe and easy it is to tolerate valrubicin at specific dose levels, as well as the way in which the drug is eliminated from the human body (Pharmacokinetics or PK).
Interventions
- DRUG Valrubicin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2012-07 |
| Est. Completion | 2016-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01606345
The ClinicalTrials.gov registry entry for NCT01606345 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is H. Lee Moffitt Cancer Center and Research Institute, which has 502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Valrubicin is the first listed.
NCT01606345 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01606345 about?
NCT01606345 is a clinical study titled "Phase I Study of Percutaneous Valrubicin for Upper Tract Urothelial Carcinoma". The purpose of this study is to learn more about how well the drug valrubicin (VALSTAR®) works to help treat the patient's cancer when administered through a nephrostomy tube inserted through their back into their kidney. The study is also being done to determine how safe and easy it is to tolerate ...
What is the current status of trial NCT01606345?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2012-07. Estimated completion is 2016-04.
What interventions are being tested in trial NCT01606345?
The interventions under investigation include: Valrubicin (DRUG).
Who is sponsoring clinical trial NCT01606345?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.